Aptamer Group Ltd, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has entered into a large-scale Optimer development and commercialisation agreement with a life science research company for over 250 targets.
The deal structure with a potential total value of multiple millions of pounds including upfront, phased payments throughout development and, further potential IP and commercial milestone payments as Optimer binders are incorporated into proteomic research products and kits.
The Optimer platform consists of three integrated discovery processes that together increase the potential target range of the oligonucleotide-based Optimer ligands, enabling the sensitive detection of novel targets in life sciences. This expanded target range can be applied to drive the understanding of how genes and proteins interact with the environment, improve the development of drugs and enhance the diagnosis of patients.
“We are delighted to provide our Optimer platform to support what has the potential to be a significant advance for the life sciences. Aptamer Group is proud to have developed an innovative platform for the selection of custom Optimer binders which can offer novel solutions that hold the key to improvements for researchers and patients worldwide.”
Dr Arron Tolley, Chief Executive Officer of Aptamer Group